Recross Cardio

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Recross Cardio sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Recross Cardio: 1 sponsored US clinical trial, 1 recruiting.

Recross Cardio sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is PFO-associated Stroke, with 1 trials.

Mid-pack sponsor footprint

Recross Cardio is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING NA

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

NCT07172464

Therapeutic Areas

PFO-associated Stroke 1
PFO 1
Cryptogenic Stroke 1
Patent Foramen Ovale 1
PFO - Patent Foramen Ovale 1

What is open in the Recross Cardio pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: PFO-associated Stroke (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Recross Cardio: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Recross Cardio sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Recross Cardio1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Recross Cardio sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Recross Cardio sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recross Cardio page

1 registered trials is a research-attention snapshot, not an endorsement of Recross Cardio or any single study.

  • 1 of Recross Cardio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • PFO-associated Stroke is the condition Recross Cardio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PFO-associated Stroke trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Recross Cardio pipeline card: 1 registered trials from official public datasets.Report a data error.